Structure Therapeutics (GPCR) Stock Forecast & Price Target

$28.25 -0.33 (-1.15%)

(As of 12/24/2024 05:19 PM ET)

Structure Therapeutics - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 7 Analyst Ratings

Sell
0

Hold
0

Buy
7

Based on 7 Wall Street analysts who have issued ratings for Structure Therapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 7 analysts, 7 have given a buy rating for GPCR.

Consensus Price Target

$86.50
206.19% Upside

According to the 7 analysts' twelve-month price targets for Structure Therapeutics, the average price target is $86.50. The highest price target for GPCR is $118.00, while the lowest price target for GPCR is $65.00. The average price target represents a forecasted upside of 206.19% from the current price of $28.25.

Get the Latest News and Ratings for GPCR and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Structure Therapeutics and its competitors.

GPCR Analyst Ratings Over Time

Type	Current Forecast 12/26/23 to 12/25/24	1 Month Ago 11/26/23 to 11/25/24	3 Months Ago 9/27/23 to 9/26/24	1 Year Ago 12/26/22 to 12/26/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	7 Buy rating(s)	6 Buy rating(s)	8 Buy rating(s)	7 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$86.50	$86.80	$88.33	$81.14
Forecasted Upside	206.19% Upside	155.22% Upside	112.70% Upside	128.44% Upside
Consensus Rating	Buy	Buy	Buy	Buy

Why I'm telling friends to avoid gold stocks (Ad)

Back in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."

And if you’d like to get your hands on this, here you go, the complete breakdown.

GPCR Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

GPCR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Structure Therapeutics Stock vs. The Competition

Type	Structure Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.81	2.51
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	206.19% Upside	26,167.05% Upside	13.49% Upside
News Sentiment Rating	Positive News See Recent GPCR News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
12/19/2024	HC Wainwright 2 of 5 stars	A. Ghosh Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00	+166.93%
12/18/2024	JMP Securities 2 of 5 stars		Reiterated Rating	Market Outperform ➝ Market Outperform	$91.00 ➝ $91.00	+210.58%
9/23/2024	Cantor Fitzgerald 4 of 5 stars	P. Agrawal Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$65.00 ➝ $65.00	+55.06%
9/23/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Overweight	$118.00	+181.49%
6/7/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$83.00 ➝ $100.00	+86.64%
5/21/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Overweight	$65.00	+81.67%
A brand new opportunity in the stock market revealed (Ad) Today, I want to unlock a brand new opportunity in the stock market… One that has been able to pay out around 100% in 5 days or less so far on REAL money… It’s all thanks to a hidden force that drives some of the BIGGEST & most repetitive moves in stocks… I call it a Gamma Pocket… Will you be the next trader to discover the power of Gamma Pockets?
2/27/2024	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Belghiti Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
10/26/2023	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$58.00 ➝ $93.00	+32.38%
10/2/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$50.00 ➝ $92.00	+58.76%
9/29/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$46.00 ➝ $97.00	+92.38%
9/29/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$50.00 ➝ $79.00	+58.35%
2/28/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$33.00	+37.50%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 08:53 AM ET.

GPCR Forecast - Frequently Asked Questions

: According to the research reports of 7 Wall Street equities research analysts, the average twelve-month stock price forecast for Structure Therapeutics is $86.50, with a high forecast of $118.00 and a low forecast of $65.00.
: 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Structure Therapeutics in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GPCR shares.
: According to analysts, Structure Therapeutics's stock has a predicted upside of 206.19% based on their 12-month stock forecasts.
: Structure Therapeutics has been rated by research analysts at HC Wainwright, and JMP Securities in the past 90 days.
: Analysts like Structure Therapeutics more than other "medical" companies. The consensus rating for Structure Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how GPCR compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Why I'm telling friends to avoid gold stocks (Ad)

And if you’d like to get your hands on this, here you go, the complete breakdown.

This page (NASDAQ:GPCR) was last updated on 12/25/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Structure Therapeutics (GPCR) Stock Forecast & Price Target